Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

About XTL Biopharmaceuticals Stock (NASDAQ:XTLB)

Advanced Chart

Key Stats

Today's Range
$1.13
$1.13
50-Day Range
$3.43
$5.20
52-Week Range
$0.86
$3.05
Volume
N/A
Average Volume
23,588 shs
Market Capitalization
$6.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

XTL Biopharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

XTLB MarketRank™: 

XTL Biopharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for XTL Biopharmaceuticals.

  • Price to Book Value per Share Ratio

    XTL Biopharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.01% of the float of XTL Biopharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    XTL Biopharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in XTL Biopharmaceuticals has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    XTL Biopharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    XTL Biopharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.01% of the float of XTL Biopharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    XTL Biopharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in XTL Biopharmaceuticals has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for XTL Biopharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.40% of the stock of XTL Biopharmaceuticals is held by institutions.

  • Read more about XTL Biopharmaceuticals' insider trading history.
Receive XTLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XTLB Stock News Headlines

XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo Finance
XTL Biopharmaceuticals names Noam Band as CEO
This Crypto Is Set to Explode in January
Free summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this means and how everyday investors like you can position themselves to potentially profit. The timing couldn't be more critical
XTL Biopharmaceuticals Appoints Noam Band as CEO
See More Headlines

XTLB Stock Analysis - Frequently Asked Questions

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) issued its quarterly earnings results on Monday, December, 30th. The biopharmaceutical company reported ($0.09) EPS for the quarter.

XTL Biopharmaceuticals shares reverse split on the morning of Friday, February 10th 2017.The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP).

Company Calendar

Last Earnings
12/30/2024
Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED-DRUGS
Sub-Industry
N/A
Current Symbol
NASDAQ:XTLB
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$450 thousand
Price / Cash Flow
N/A
Book Value
$1.00 per share
Price / Book
1.13

Miscellaneous

Free Float
3,869,000
Market Cap
$6.16 million
Optionable
Not Optionable
Beta
1.09
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:XTLB) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners